| abstract |
Described are anti-CD148 antibodies and antigen binding regions thereof, and pharmaceutical compositions comprising such antibodies and antigen binding regions. Also described are methods using these antibodies and antigen binding regions to bind to CD148 epitopes and activate CD148 function, eg, angiogenesis inhibition. Also described are methods of identifying epitopes that can be used to activate CD148 function and anti-angiogenic activity, and agents that can bind to such epitopes. |